| 2.425 -0.015 (-0.61%) | 04-19 15:10 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.57 |
1-year : | 4.02 |
| Resists | First : | 3.06 |
Second : | 3.45 |
| Pivot price | 2.86 |
|||
| Supports | First : | 2.44 |
Second : | 2.03 |
| MAs | MA(5) : | 2.64 |
MA(20) : | 2.91 |
| MA(100) : | 3.8 |
MA(250) : | 6.43 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 7.3 |
D(3) : | 10.6 |
| RSI | RSI(14): 24.4 |
|||
| 52-week | High : | 12.35 | Low : | 2.44 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CVAC ] has closed below the lower bollinger band by 7.6%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ CVAC ] is to continue within current trading range. Bollinger Bands are 3.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.73 - 2.75 | 2.75 - 2.76 |
| Low: | 2.5 - 2.52 | 2.52 - 2.53 |
| Close: | 2.54 - 2.57 | 2.57 - 2.59 |
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.
Tue, 16 Apr 2024
CureVac, MD Anderson teams up for cancer vaccines (NASDAQ:CVAC) - Seeking Alpha
Mon, 15 Apr 2024
CureVac (NASDAQ:CVAC) Stock Price Down 4.8% - MarketBeat
Thu, 04 Apr 2024
CureVac stock gains on data for GSK-partnered flu shot (NASDAQ:CVAC) - Seeking Alpha
Sat, 02 Mar 2024
CVAC Stock Quote Price and Forecast - CNN
Fri, 26 Jan 2024
Down -14.25% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC) - Yahoo Finance
Thu, 11 Jan 2024
CureVac N.V.'s (NASDAQ:CVAC) market cap dropped US$69m last week; Individual investors bore the brunt - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 224 (M) |
| Shares Float | 119 (M) |
| Held by Insiders | 45.4 (%) |
| Held by Institutions | 23.7 (%) |
| Shares Short | 5,010 (K) |
| Shares Short P.Month | 4,390 (K) |
| EPS | -1.59 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.69 |
| Profit Margin | 0 % |
| Operating Margin | -333 % |
| Return on Assets (ttm) | -18.1 % |
| Return on Equity (ttm) | -49.3 % |
| Qtrly Rev. Growth | 47 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.19 |
| EBITDA (p.s.) | -1.09 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -273 (M) |
| Levered Free Cash Flow | -211 (M) |
| PE Ratio | -1.55 |
| PEG Ratio | 0.2 |
| Price to Book value | 0.9 |
| Price to Sales | 12.74 |
| Price to Cash Flow | -2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|